First Seizure & Acute Symptomatic
First Seizure Evaluation & Acute Symptomatic Seizures
What Do You Need to Know?
- First unprovoked seizure: 40–50% recurrence risk at 2 years; early treatment reduces early recurrence but does NOT alter long-term remission rates (FIRST & MESS trials)
- Treat after first seizure when recurrence risk ≥60%: epileptiform EEG, remote structural lesion, nocturnal seizure, or epileptiform EEG + known etiology
- Acute symptomatic seizures: occur within 7 days of structural insult or during active metabolic derangement; account for ~40% of all new-onset seizures; are NOT epilepsy
- Recurrence risk: acute symptomatic seizures carry 3–10× lower recurrence risk than a first unprovoked seizure
- Treatment priority: correct the underlying cause; long-term ASMs generally NOT indicated for isolated acute symptomatic seizures
- Key specifics: phenytoin is NOT effective for alcohol withdrawal seizures (use BZDs); eclampsia requires IV MgSO4, NOT standard ASMs; post-TBI 7-day prophylaxis does NOT prevent late epilepsy
First Unprovoked Seizure
Recurrence Risk
- Overall: 40–50% at 2 years without treatment
- With epileptiform EEG: 60–70% at 2 years
- With remote structural lesion: 60–70% at 2 years
- Nocturnal seizure: higher than baseline
- Two or more risk factors: typically ≥60% → meets ILAE epilepsy definition
Key Evidence: FIRST & MESS Trials
- Immediate ASM treatment reduces recurrence by ~35% over 2 years
- Critical point: early treatment does NOT alter the long-term remission rate at 5 years
- Patients who defer treatment until a second seizure achieve the SAME long-term seizure freedom
When to Treat After First Seizure
Indications Favoring Treatment (recurrence risk ≥60%)
- EEG with interictal epileptiform discharges (IEDs)
- Remote structural brain lesion concordant with seizure type
- Nocturnal seizure + additional risk factor
- Epileptiform EEG + known etiology
- Identification of an epilepsy syndrome (e.g., JME)
Indications Favoring Deferral
- Normal EEG, normal MRI, no risk factors
- Acute symptomatic seizure with correctable cause
- Patient preference after informed discussion
- Concerns about teratogenicity, cognitive side effects, or drug interactions
💎 Board Pearl
- AAN/AES guidelines: treatment decision after a first seizure should be individualized based on recurrence risk, patient preferences, and risk-benefit analysis
- A single unprovoked seizure + ≥60% recurrence risk = can diagnose epilepsy per ILAE 2014 definition (no need to wait for a second seizure)
Acute Symptomatic Seizures — Definition & Framework
ILAE Operational Definition
- Structural causes: seizure within 7 days of acute brain insult (stroke, TBI, CNS infection, neurosurgery)
- Metabolic/toxic causes: seizure during the active phase of the metabolic derangement
- CNS infections: seizure during active infection (may extend beyond 7 days)
- Account for ~40% of all new-onset seizures; incidence ~29–39 per 100,000/year
Why the Distinction Matters
- Acute symptomatic seizures are NOT epilepsy — even when recurrent
- 3–10× lower recurrence risk vs. first unprovoked seizure
- ~20% develop epilepsy within 10 years
- Mislabeling as epilepsy → unnecessary long-term ASMs, driving restrictions, psychosocial burden
Terminology Table
| Term | Definition | Clinical Significance |
|---|---|---|
| Acute symptomatic | Seizure within 7 days of acute insult or during active metabolic derangement | Provoked; NOT epilepsy; treat underlying cause |
| Unprovoked | No identifiable proximate cause or >7 days after brain insult | 2 unprovoked >24h apart = epilepsy; 1 + ≥60% recurrence = epilepsy |
| Early seizure | Seizure ≤7 days of TBI or stroke | Acute symptomatic; short-term treatment may be indicated |
| Late seizure | Seizure >7 days after TBI or stroke | Unprovoked; constitutes post-traumatic/post-stroke epilepsy |
| Remote symptomatic | Unprovoked seizure with prior brain insult >7 days earlier | Higher recurrence (~65%); generally warrants ASM |
Metabolic Thresholds for Acute Symptomatic Seizures
| Metabolic Cause | Seizure Threshold | Key Notes |
|---|---|---|
| Hypoglycemia | ≤36 mg/dL (2.0 mmol/L) | IV dextrose (D50W); seizures resolve with glucose correction |
| Hyperglycemia (nonketotic) | ≥400 mg/dL without ketosis | Focal motor seizures/EPC characteristic; ASMs often ineffective until glucose corrected |
| Hyponatremia | ≤115 mEq/L (or rapid drop) | 3% hypertonic saline; avoid overcorrection (≤10–12 mEq/L/24h) — osmotic demyelination |
| Hypocalcemia | ≤5.0 mg/dL (ionized <0.8) | IV calcium gluconate; correct concurrent hypomagnesemia |
| Hypomagnesemia | ≤0.8 mg/dL | IV MgSO4; Mg2+ is endogenous NMDA blocker; must correct to enable Ca normalization |
| Uremia | Variable (BUN often ≥100) | Dialysis; avoid rapid urea clearance (dialysis disequilibrium); LEV preferred ASM |
| Hepatic encephalopathy | Variable | Lactulose, rifaximin; avoid valproate; often with asterixis |
💎 Board Pearl
- Nonketotic hyperglycemia + focal motor seizures/EPC = classic board association; ASMs often ineffective until glucose corrected
- Hypomagnesemia causes refractory hypocalcemia — always check and correct Mg first
Alcohol Withdrawal Seizures
Timeline & Features
- Peak incidence: ~24 hours after last drink (range 12–48 hours)
- Usually single or brief cluster of GTCS (1–3 seizures)
- Occur in 5–15% of chronic alcohol users undergoing withdrawal
- Mechanism: chronic GABA-A downregulation + NMDA upregulation → hyperexcitability on cessation
| Time After Last Drink | Manifestation |
|---|---|
| 6–12 hours | Tremor, anxiety, tachycardia, diaphoresis, insomnia |
| 12–48 hours | Withdrawal seizures (peak at 24h); alcoholic hallucinosis |
| 48–96 hours | Delirium tremens (3–5%; mortality 1–4% treated) |
Management
- BZDs are treatment of choice: lorazepam 2–4 mg IV for active seizures; CIWA-guided dosing
- Phenytoin is NOT effective — multiple RCTs show no benefit
- Phenobarbital: alternative first-line; 10–20 mg/kg IV loading
- Long-term ASMs NOT indicated for isolated alcohol withdrawal seizures
- Thiamine: IV (100–500 mg) BEFORE glucose to prevent Wernicke
- Withdrawal seizure patients: 30% risk of progressing to delirium tremens
- Kindling: repeated withdrawal episodes → progressive worsening of seizures
Drug-Related Seizures
| Category | Examples | Notes |
|---|---|---|
| Toxicity / overdose | Theophylline, tramadol, bupropion, isoniazid, lithium, TCAs, fluoroquinolones, carbapenems (imipenem > meropenem) | Dose-dependent; treat with BZDs; INH → pyridoxine 5 g IV |
| Recreational drugs | Cocaine, amphetamines, MDMA, synthetic cannabinoids, PCP | Sympathomimetic toxicity; hyperthermia; MDMA may cause hyponatremia |
| Withdrawal | BZDs, barbiturates, baclofen, GHB, alcohol | GABA-A downregulation mechanism; BZD withdrawal may be delayed (depends on half-life) |
| PRES-causing agents | Cyclosporine, tacrolimus, bevacizumab, cisplatin | Endothelial dysfunction, vasogenic edema (occipital/parietal); BP control is primary treatment |
High-Yield Drug-Seizure Associations
- Bupropion: dose-dependent seizure risk; highest of all antidepressants; contraindicated in eating disorders (electrolyte imbalance)
- Tramadol: lowers seizure threshold via serotonin/norepinephrine reuptake inhibition + weak opioid activity; risk increases with concurrent SSRIs
- Carbapenems: imipenem has highest seizure risk among carbapenems; meropenem and doripenem are safer alternatives in patients with seizure history
- Cyclosporine/tacrolimus: calcineurin inhibitor toxicity can cause PRES with seizures even at therapeutic drug levels; MRI shows posterior vasogenic edema
- Baclofen withdrawal: can cause seizures, autonomic instability, and hyperthermia resembling NMS; occurs with sudden discontinuation of intrathecal or oral baclofen
Clinical Pearl
Isoniazid toxicity causes refractory seizures by depleting pyridoxine (vitamin B6), which is essential for GABA synthesis. The antidote is pyridoxine 5 g IV (gram-for-gram matching of INH ingested if known). Standard ASMs alone are often ineffective without pyridoxine repletion.
Post-Stroke Seizures
Incidence & Classification
- Early (≤7 days): 2–6% ischemic, 10–16% hemorrhagic — acute symptomatic
- Late (>7 days): 3–5% ischemic, 5–10% hemorrhagic — constitutes post-stroke epilepsy
- CVT seizures: 30–40% — highest rate among cerebrovascular causes
- Cortical involvement = strongest risk factor; early seizures increase late epilepsy risk 2–3-fold
Management
- Primary ASM prophylaxis NOT recommended (AHA/ASA)
- Early post-stroke seizure: short-term ASM (7–14 days); reassess at follow-up
- Late post-stroke seizure: long-term ASM indicated — this is epilepsy
- Avoid enzyme-inducing ASMs (CBZ, PHT, PB) — interact with statins, anticoagulants
- Preferred: levetiracetam or lacosamide (fewest drug interactions)
- CVT-associated seizures: treat acute seizures; prophylactic ASMs reasonable given high seizure rate (30–40%)
💎 Board Pearl
- Primary ASM prophylaxis after stroke = NOT recommended — no evidence of benefit; potential for sedation, falls, drug interactions
- Hemorrhagic stroke has 2–3× higher seizure incidence than ischemic stroke
- CVT has the highest seizure rate (30–40%) of all cerebrovascular causes
Post-TBI Seizures
Risk by Severity
| TBI Severity | Late Epilepsy Risk | Prophylaxis |
|---|---|---|
| Mild (GCS 13–15) | ~0.5–2% | Not recommended |
| Moderate (GCS 9–12) | ~1.2–10% | Consider 7-day prophylaxis |
| Severe (GCS ≤8) | 10–17% | Recommended: PHT or LEV × 7 days |
| Penetrating TBI | 35–50% | Strongly recommended |
Key Principles
- 7-day prophylaxis for severe TBI reduces EARLY seizures only
- Does NOT prevent late (post-traumatic) epilepsy — multiple RCTs confirm
- LEV preferred over PHT: fewer interactions, no drug monitoring, better side effect profile
- Subclinical seizures in 20–30% of moderate-to-severe TBI on continuous EEG
Specific Reversible Causes
Eclampsia
- Seizures in setting of preeclampsia (HTN + proteinuria after 20 weeks gestation)
- Pathophysiology: endothelial dysfunction, vasospasm, vasogenic edema (PRES)
- IV MgSO4 is treatment of choice (4–6 g loading, then 1–2 g/hr)
- Standard ASMs generally NOT needed and may be harmful
- BP control (labetalol, hydralazine, nicardipine) + delivery
Isoniazid Toxicity
- INH depletes pyridoxine (B6) → impaired GABA synthesis → refractory seizures
- Antidote: pyridoxine 5 g IV (gram-for-gram if ingested amount known)
- Standard ASMs alone are often ineffective
Nonketotic Hyperglycemia
- Focal motor seizures and EPC are characteristic
- Hyperosmolarity → neuronal dehydration → cortical irritability
- ASMs often ineffective until glucose corrected; gradual insulin + fluids
Seizure Clusters & Rescue Therapy
Definition
- ≥2 seizures within 24 hours in someone with epilepsy (for patients with typically ≤1 seizure/day)
- 20–30% of patients with epilepsy experience clusters
- Risk: progression to status epilepticus if untreated
Rescue Medication Options
| Product | Route | Onset | Key Features |
|---|---|---|---|
| Nayzilam (midazolam) | Intranasal | 3–5 min | Fastest onset; 5 mg fixed dose; ≥12 years; water-soluble |
| Valtoco (diazepam) | Intranasal | 5–15 min | Weight-based dosing; ≥2 years (2025); longer duration |
| Diastat (diazepam) | Rectal | 5–15 min | Oldest approved; 0.2–0.5 mg/kg; social barriers |
| Buccal midazolam | Buccal | 5–10 min | EU-approved (Buccolam); off-label in US |
Patient / Caregiver Action Plan
- Every at-risk patient should have a written seizure action plan
- Specifies: when to give rescue medication, correct dose, when to call 911
- Call 911 if: seizure >5 min, no recovery between seizures, rescue fails, respiratory compromise
- Frequent rescue use (>1–2 episodes/month) → reassess baseline ASM regimen
Board Pearls
💎 Board Pearl
- Phenytoin is NOT effective for alcohol withdrawal seizures — BZDs are treatment of choice; they directly address the GABA deficit; perennial board favorite
- Early treatment after first seizure reduces early recurrence but does NOT change long-term remission — FIRST and MESS trials; deferring treatment does not worsen prognosis
- Acute symptomatic seizure ≠ epilepsy — 7-day window for structural causes; recurrence risk 3–10× lower than first unprovoked seizure
- Post-TBI seizure prophylaxis = 7 days only, severe TBI only — PHT or LEV prevents early seizures but does NOT prevent post-traumatic epilepsy
- Eclampsia = IV MgSO4, NOT standard ASMs — MgSO4 superior to PHT and diazepam (Magpie trial)
- Isoniazid toxicity = pyridoxine 5 g IV — standard ASMs fail without pyridoxine repletion
- Nonketotic hyperglycemia + focal motor seizures/EPC = classic board association; ASMs often resistant until glucose corrected
Clinical Pearls
Clinical Pearl
Late post-stroke seizure (>7 days) = post-stroke epilepsy. Avoid enzyme-inducing ASMs (CBZ, PHT, PB) in stroke patients due to interactions with statins, anticoagulants, and antihypertensives. LEV and lacosamide are preferred. Primary ASM prophylaxis after stroke is NOT recommended (AHA/ASA).
Clinical Pearl
The 7-day boundary is the critical line. A seizure on day 5 after stroke = acute symptomatic (provoked). A seizure on day 10 = unprovoked = epilepsy. This distinction determines long-term ASM need, driving restrictions, and psychosocial implications.
Clinical Pearl
Intranasal midazolam (Nayzilam) has the fastest onset (~3–5 min) of non-IV rescue formulations because midazolam is water-soluble and readily absorbed through nasal mucosa without special excipients. Diazepam (Valtoco) requires an absorption enhancer (Intravail) because it is lipophilic.
References
- Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults. Neurology. 2015;84(16):1705–1713.
- Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671–675.
- Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
- Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009;50(5):1102–1108.
- Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323(8):497–502.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy. Lancet. 2007;369(9566):1016–1026.
- Hillbom M, Pieninkeroinen I, Leone M. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs. 2003;17(14):1013–1030.
- Holtkamp M, Beghi E, Bhatt A, et al. European Stroke Organisation guidelines for post-stroke seizures and epilepsy. Eur Stroke J. 2024;9(1):78–103.
- Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591–600.
- Detyniecki K, Van Ess PJ, Bhatt AB, et al. Safety and efficacy of midazolam nasal spray for seizure clusters. Epilepsia. 2019;60(3):507–514.
- Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? Lancet. 2002;359(9321):1877–1890.
- Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized trial of IV levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165–172.